291 related articles for article (PubMed ID: 20310000)
1. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R
Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
[TBL] [Abstract][Full Text] [Related]
6. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
7. [Reinduction therapy with gemtuzumab ozogamicin for relapsed or refractory CD33-positive acute myelogeneous leukemia].
Shimokawa T; Kojima Y
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1427-30. PubMed ID: 18701865
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
11. Ab therapy of AML: native anti-CD33 Ab and drug conjugates.
Jurcic JG
Cytotherapy; 2008; 10(1):7-12. PubMed ID: 17917880
[TBL] [Abstract][Full Text] [Related]
12. Antibody therapy for acute myeloid leukemia.
Mulford D
Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
van der Heiden PL; Jedema I; Willemze R; Barge RM
Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432
[TBL] [Abstract][Full Text] [Related]
14. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
15. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
16. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
17. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
[No Abstract] [Full Text] [Related]
18. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.
Pagano L; Fianchi L; Caira M; Rutella S; Leone G
Oncogene; 2007 May; 26(25):3679-90. PubMed ID: 17530021
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Giles F; Estey E; O'Brien S
Cancer; 2003 Nov; 98(10):2095-104. PubMed ID: 14601078
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
